MASLD-Related Hepatocarcinoma: Special Features and Challenges

Area of Science:

• Hepatology
• Oncology
• Metabolic Diseases

Background:

• Metabolic-associated steatohepatitis liver disease (MASLD) is a growing global health concern, affecting 25% of the population.
• MASLD is increasingly linked to hepatocellular carcinoma (HCC), with a rising incidence.
• HCC in MASLD patients can occur without cirrhosis, leading to late-stage diagnosis and poorer prognoses.

Purpose of the Study:

• To highlight the rising incidence of hepatocellular carcinoma (HCC) in patients with metabolic-associated steatohepatitis liver disease (MASLD).
• To emphasize the diagnostic challenges and the need for improved risk stratification in MASLD-associated HCC.
• To discuss the current landscape of therapeutic approaches for preventing HCC in the context of MASLD.

Main Methods:

• Literature review of epidemiological data on MASLD and HCC.
• Analysis of clinical presentation and diagnostic patterns of HCC in MASLD.
• Overview of ongoing research into preventative therapies for MASLD-related HCC.

Main Results:

• MASLD prevalence is substantial and projected to increase globally.
• A significant proportion of HCC cases arise in the context of MASLD, often without preceding cirrhosis.
• Current screening and therapeutic strategies for MASLD-associated HCC are not standardized.

Conclusions:

• Accurate identification of high-risk individuals with MASLD is essential for targeted HCC screening.
• Further research is needed to establish effective guidelines for HCC prevention in MASLD patients.
• Addressing the rising burden of MASLD-related HCC requires a multi-faceted approach including early detection and novel therapies.